Zacks Investment Research upgraded shares of Corium International (NASDAQ:CORI) from a hold rating to a buy rating in a report released on Thursday. Zacks Investment Research currently has $13.00 price objective on the biopharmaceutical company’s stock.
According to Zacks, “Corium International, Inc. is a commercial-stage biopharmaceutical company. It is focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage advanced technologies in transdermal and transmucosal delivery systems. Corium has developed six marketed products in the prescription drug and consumer markets: Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain and four Crest Advanced Seal Whitestrips products. The company has two proprietary transdermal technology platforms with applications in multiple drug categories and indications: Corplex(TM) and MicroCor(R). Corium International, Inc. is headquartered in Menlo Park, California. “
Several other research analysts also recently commented on CORI. BidaskClub downgraded Corium International from a buy rating to a hold rating in a research report on Tuesday, March 13th. HC Wainwright set a $14.00 price target on Corium International and gave the stock a buy rating in a research report on Friday, February 9th. ValuEngine raised Corium International from a sell rating to a hold rating in a research report on Sunday, December 31st. Needham & Company LLC dropped their price target on Corium International from $16.00 to $14.00 and set a buy rating on the stock in a research report on Tuesday, December 26th. Finally, Cantor Fitzgerald reaffirmed a buy rating and issued a $14.00 price target on shares of Corium International in a research report on Friday, December 22nd. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Corium International presently has a consensus rating of Buy and an average target price of $13.00.
Corium International (NASDAQ:CORI) last issued its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.06. The company had revenue of $9.32 million for the quarter, compared to the consensus estimate of $7.48 million. Corium International had a negative return on equity of 403.15% and a negative net margin of 148.07%. equities research analysts predict that Corium International will post -1.47 EPS for the current year.
In other news, major shareholder Life Sciences Maste Perceptive acquired 510,000 shares of the firm’s stock in a transaction dated Thursday, January 18th. The shares were bought at an average price of $12.54 per share, with a total value of $6,395,400.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Perceptive Advisors Llc acquired 50,350 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The shares were purchased at an average cost of $11.83 per share, for a total transaction of $595,640.50. The disclosure for this purchase can be found here. Insiders own 30.80% of the company’s stock.
Large investors have recently made changes to their positions in the company. MetLife Investment Advisors LLC acquired a new stake in shares of Corium International during the 4th quarter worth approximately $123,000. New York State Common Retirement Fund acquired a new stake in shares of Corium International during the 2nd quarter worth approximately $158,000. California State Teachers Retirement System acquired a new stake in shares of Corium International during the 2nd quarter worth approximately $263,000. California Public Employees Retirement System acquired a new stake in shares of Corium International during the 4th quarter worth approximately $310,000. Finally, Two Sigma Advisers LP acquired a new stake in shares of Corium International during the 4th quarter worth approximately $317,000. 88.58% of the stock is currently owned by institutional investors.
WARNING: This article was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3301980/corium-international-cori-upgraded-by-zacks-investment-research-to-buy.html.
Corium International Company Profile
Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.